Search results

102 results for All evidence

Sorted by Relevance . Sort by Date

Showing results 61 to 70. View options for downloading these results.

Displaying only NeLM Legacy Drug best practice guidance for your search.
Return to full search results.

  • dalbavancin (Xydalba®)

    Source:
    All Wales Medicines Strategy Group - AWMSG (Remove filter)

    Published by All Wales Medicines Strategy Group, 25 July 2018

    Dalbavancin is recommended for restricted use within NHS Wales for 2nd line treatment of acute bacterial skin and skin structure infections in adults, or when MRSA infection is suspected; and the...

    Read Summary

    Type:
    Prescribing and Technical Information (Remove filter)
  • ciprofloxacin (Cetraxal®)

    Source:
    All Wales Medicines Strategy Group - AWMSG (Remove filter)

    Published by All Wales Medicines Strategy Group, 25 July 2018

    Cetraxal is recommended as an option for use within NHS Wales for the treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by...

    Read Summary

    Type:
    Prescribing and Technical Information (Remove filter)
  • icatibant acetate (Firazyr®)

    Source:
    All Wales Medicines Strategy Group - AWMSG (Remove filter)

    Published by All Wales Medicines Strategy Group, 14 June 2018

    This is recommended for use in NHS Wales for symptomatic treatment of acute attacks of hereditary angioedema in adults, adolescents and children aged 2 years and older, with C1 esterase-inhibitor...

    Read Summary

    Type:
    Prescribing and Technical Information (Remove filter)
  • ranibizumab (Lucentis®)

    Source:
    All Wales Medicines Strategy Group - AWMSG (Remove filter)

    Published by All Wales Medicines Strategy Group, 14 June 2018

    This is recommended for use in NHS Wales for treatment of visual impairment in adults due to choroidal neovascularisation not due to pathological myopia or wet age-related macular degeneration, ...

    Read Summary

    Type:
    Prescribing and Technical Information (Remove filter)
  • selexipag (Uptravi®)

    Source:
    All Wales Medicines Strategy Group - AWMSG (Remove filter)

    Published by All Wales Medicines Strategy Group, 14 June 2018

    This is recommended for restricted use in NHS Wales as triple therapy for pulmonary arterial hypertension (WHO functional class III) in adults who are insufficiently controlled on dual therapy with...

    Read Summary

    Type:
    Prescribing and Technical Information (Remove filter)
  • levonorgestrel (Kyleena®)

    Source:
    All Wales Medicines Strategy Group - AWMSG (Remove filter)

    Published by All Wales Medicines Strategy Group, 26 September 2018

    Levonorgestrel (Kyleena®) is recommended as an option for use within NHS Wales for contraception for up to five years. Levonorgestrel (Kyleena®) should be prescribed by brand name to avoid medication...

    Read Summary

    Type:
    Prescribing and Technical Information (Remove filter)
  • octreotide (Sandostatin® LAR®)

    Source:
    All Wales Medicines Strategy Group - AWMSG (Remove filter)

    Published by All Wales Medicines Strategy Group, 26 September 2018

    Octreotide (Sandostatin® LAR®) is recommended as an option for use within NHS Wales for the treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where...

    Read Summary

    Type:
    Prescribing and Technical Information (Remove filter)
  • lanreotide (Somatuline® Autogel®)

    Source:
    All Wales Medicines Strategy Group - AWMSG (Remove filter)

    Published by All Wales Medicines Strategy Group, 26 September 2018

    Lanreotide (Somatuline® Autogel®) is recommended as an option for use within NHS Wales for treatment of grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumours in adult patients...

    Read Summary

    Type:
    Prescribing and Technical Information (Remove filter)
  • Glycerol phenylbutyrate (Ravicti) approved in NHS Wales for use as adjunctive therapy for chronic management of patients with urea cycle disorders

    Source:
    All Wales Medicines Strategy Group - AWMSG (Remove filter)

    Published by All Wales Medicines Strategy Group, 17 December 2019

    This includes patients with the conditions CPS, OTC, ASS, ASL, ARG and HHH, who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It must be used with dietary...

    Read Summary

    Type:
    Prescribing and Technical Information (Remove filter)
  • Fampridine (Fampyra) is recommended for use within NHS Wales for patients with multiple sclerosis

    Source:
    All Wales Medicines Strategy Group - AWMSG (Remove filter)

    Published by All Wales Medicines Strategy Group, 17 December 2019

    It is recommended as option for improvement of walking in adult patients with walking disability (Expanded Disability Status Scale 4 to 7), providing approved Wales Patient Access Scheme (WPAS) is...

    Read Summary

    Type:
    Prescribing and Technical Information (Remove filter)

Results per page | | |